Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 6/20 | 0.42 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.42 |
| ▸ | ABAT | P80404 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18279482 | 0.81 | ALDH1A1 (0.54) | KDM4ESMN1; SMN2 | |
| SCHEMBL27404004 | 0.80 | KEAP1 (0.44) | HRH3LOXL2PSIP1ABATCA1 | |
| SCHEMBL20438385 | 0.80 | ALDH1A1 (0.39) | — | |
| SCHEMBL27898878 | 0.77 | MAPK1 (0.39) | CA2MAPTTAAR1SMN1; SMN2 | |
| SCHEMBL5109986 | 0.74 | PSIP1 (0.44) | HRH3LOXL2PSIP1ABATCA1 | |
| SCHEMBL295816 | 0.73 | ALDH1A1 (0.64) | HRH3LOXL2ABATMAPTKEAP1 | |
| SCHEMBL924268 | 0.73 | TDP1 (0.52) | CA1CA2CA12CA4CA6 | |
| Ethylamine SCHEMBL29204897 | 0.73 | TAAR1 (0.41) | MAPTTAAR1KDM4ESMN1; SMN2 | |
| SCHEMBL12304286 | 0.72 | ALDH1A1 (0.35) | MAPTKDM4E | |
| SCHEMBL20438389 | 0.72 | SMN1; SMN2 (0.37) | HRH3MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306566-B1 | CURABLE RESIN COMPOSITION, CURED PRODUCT AND ADHESIVE | ADEKA CORP (JP) | 2026-05-06 | — | — | EP | disclosed |
| US-12590178-B2 | Curable resin composition and method for suppressing curing shrinkage of curable resin composition | ADEKA CORPORATION (JP) | 2026-03-31 | — | — | US | disclosed |
| EP-4306567-B1 | CURABLE RESIN COMPOSITION, CURED PRODUCT, AND ADHESIVE | ADEKA CORP (JP) | 2025-06-04 | — | — | EP | disclosed |
| US-12269917-B2 | Curable resin composition | ADEKA CORPORATION (JP) | 2025-04-08 | — | — | US | disclosed |
| US-20250109240-A1 | ONE-PACK TYPE EPOXY RESIN COMPOSITION | ADEKA CORPORATION (JP) | 2025-04-03 | — | — | US | disclosed |
| WO-2025062839-A1 | COMPOUND, EPOXY RESIN, CURABLE COMPOSITION, MATERIAL FOR RECYCLING, CURED ARTICLE, METHOD FOR PRODUCING CURED ARTICLE, METHOD FOR PRODUCING DECOMPOSITION PRODUCT, AND DECOMPOSITION METHOD | 株式会社ADEKA | 2025-03-27 | — | — | WO | disclosed |
| WO-2025047655-A1 | BLOCK URETHANE MATERIAL, COMPOSITION, CURED PRODUCT, METHOD FOR PRODUCING CURED PRODUCT, AND BLOCK URETHANE COMPOUND CONTAINED THEREIN | 株式会社ADEKA | 2025-03-06 | — | — | WO | disclosed |
| EP-4491653-A1 | ONE-PACK TYPE EPOXY RESIN COMPOSITION | ADEKA CORPORATION (JP) | 2025-01-15 | — | — | EP | disclosed |
| US-20250002707-A1 | CURABLE RESIN COMPOSITION, CURED PRODUCT, AND ADHESIVE | ADEKA CORPORATION (JP) | 2025-01-02 | — | — | US | disclosed |
| US-20240409681-A1 | CLATHRATE COMPOUND, EPOXY RESIN CURING AGENT, AND CURABLE RESIN COMPOSITION | ADEKA CORPORATION (JP) | 2024-12-12 | — | — | US | disclosed |
| EP-4029896-A1 | CURABLE RESIN COMPOSITION | ADEKA CORPORATION (JP) | 2022-07-20 | — | — | EP | disclosed |
| US-20220185946-A1 | CURABLE RESIN COMPOSITION | ADEKA CORPORATION (JP) | 2022-06-16 | — | — | US | disclosed |
| CN-114207039-A | Curable resin composition | 株式会社艾迪科 | 2022-03-18 | — | — | CN | disclosed |
| EP-3950761-A1 | CURABLE RESIN COMPOSITION | ADEKA CORPORATION (JP) | 2022-02-09 | — | — | EP | disclosed |
| EP-2653492-B1 | MASTERBATCH-TYPE LATENT CURING AGENT FOR EPOXY RESIN, AND EPOXY RESIN COMPOSITION USING THE SAME | ADEKA CORP (JP) | 2021-03-03 | — | — | EP | disclosed |
| US-9464161-B2 | Masterbatch-type latent curing agent for epoxy resin, and epoxy resin composition using the same | ADEKA CORPORATION (JP) | 2016-10-11 | — | — | US | disclosed |
| US-8911586-B2 | One liquid type cyanate-epoxy composite resin composition | ADEKA CORPORATION (JP) | 2014-12-16 | — | — | US | disclosed |
| EP-2653492-A1 | MASTERBATCH-TYPE LATENT CURING AGENT FOR EPOXY RESIN, AND EPOXY RESIN COMPOSITION USING THE SAME | Adeka Corporation (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-20130267663-A1 | MASTERBATCH-TYPE LATENT CURING AGENT FOR EPOXY RESIN, AND EPOXY RESIN COMPOSITION USING THE SAME | ADEKA CORPORATION (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20110095453-A1 | ONE LIQUID TYPE CYANATE-EPOXY COMPOSITE RESIN COMPOSITION | ADEKA CORPORATION (JP) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590178-B2 | Curable resin composition and method for suppressing curing shrinkage of curable resin composition | SEM1, RER1, JMJD6 | HRH3 1384/4885LOXL2 828/4885PSIP1 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.